Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 9 - Drugs for disorders of the cardiovascular system
Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484)
04/2003
04/03/2003WO2003026673A1 Modulation of vitamin storage
04/03/2003WO2003026672A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
04/03/2003WO2003026668A1 Ophthalmologic treatment methods using selective inos inhibitors
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026660A1 An enantiomerically pure diarylmethylpiperazine and methods of using same
04/03/2003WO2003026652A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
04/03/2003WO2003026648A1 4,5-dihydro-1h-pyrazole derivatives having potent cb1-antagonistic activity
04/03/2003WO2003026647A1 Novel 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
04/03/2003WO2003026644A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
04/03/2003WO2003026638A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003WO2003026636A1 Thrombus/thrombogenesis inhibitors
04/03/2003WO2003026622A1 Lisinopril compositions having large-particle dcpd
04/03/2003WO2003026590A2 Biological control of nanoparticles
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026492A2 Prevention and treatment of restenosis by local administration of drug
04/03/2003WO2003026408A1 Model animal with overexpression of regucalcin
04/03/2003WO2003007921A3 Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002089736A3 Adenosine a1 receptor antagonists for treating hypoxia-induced learning and memory impairment
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002076460A3 Use of propentofylline to control intraocular pressure
04/03/2003WO2002073213A3 Assay
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002062330A3 Use of (r)-ibuprofen methanesulfonamide and salts thereof in the treatment and prevention of rejection reactions of transplanted organs
04/03/2003WO2002057413A3 Peptides for activation and inhibition of delta pkc
04/03/2003WO2002056753A3 P27 prevents cellular migration
04/03/2003WO2002039954A3 Novel compounds
04/03/2003WO2002034248A3 METHOD FOR INCREASING TISSUE PERFUSION BY CO-ADMINISTRATION OF AN AGENT THAT INCREASES cGMP SYNTHESIS AND AN AGENT THAT INHIBITS cGMP DEGRADATION
04/03/2003WO2002030400A1 Solid preparations
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002011703A9 Hybrid neuroprosthesis for the treatment of brain disorders
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030065382 Means and method for the treatment of coronary artery obstructions
04/03/2003US20030065377 Coated medical devices
04/03/2003US20030065195 Ether compounds
04/03/2003US20030065179 Diabetic therapy
04/03/2003US20030065176 Anticoagulant; cardiovascular disorders
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065040 Hypotensive agents
04/03/2003US20030065038 Administering N-propargyl-1-aminoindan
04/03/2003US20030065030 Containing carnosine; therapy for nervous system disorders
04/03/2003US20030065023 Anticancer agents, viricides, psychological disorders
04/03/2003US20030065010 Preparation of anhydrous cetp inhibitor
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064999 Therapy for asthma, diarrhea
04/03/2003US20030064996 Anticarcinogenic agents, antiinflammatory agents, anticholesterol agents, antidiabetic agents
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064967 Using probucol ester
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064935 Amino acid complexes of C-aryl glucosides for treatment of diabetes and method
04/03/2003US20030064933 Transdermal administration of ACE inhibitors
04/03/2003US20030064919 Novel polypeptides and polynucleotides encoding same
04/03/2003US20030064475 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins and uses thereof
04/03/2003US20030064426 Expression vector for use in the treatment of cancer and age-related defects
04/03/2003US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
04/03/2003US20030064374 Detecting neuronal stress in humans; obtain sample, measure phosphodiesterase concentration, evaluate for neuronal stress
04/03/2003US20030064369 Novel proteins and nucleic acids encoding same
04/03/2003US20030064114 For vasodilatation and inhibition of transplant rejection
04/03/2003US20030064098 Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
04/03/2003US20030064097 For delivery of drugs, nutrionals, cosmeceuticals and diagnostic agents
04/03/2003US20030064088 Surgically implantable and sealable drug delivery device that upon contact of its contents via an interface window or port with an organ or tissue exposes a therapeutic agent to organ or tissue surface, allowing a controlled, selective diffusion
04/03/2003US20030064068 Antithrombotic agent and humanized anti-von willebrand factor monoclonal antibody
04/03/2003US20030064052 Useful for maintaining controlled and reliable dosage of the therapeutic agent via pulmonary delivery
04/03/2003US20030064036 Coating and binding agent for pharmaceutical formulations with improved storage stability
04/03/2003CA2726702A1 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
04/03/2003CA2463039A1 1,6-naphthyridine derivatives as antidiabetics
04/03/2003CA2461898A1 Biological control of nanoparticles
04/03/2003CA2461806A1 Water-soluble phenylpyridazine derivatives and medicines containing the same
04/03/2003CA2461705A1 Coadministration of transport protein with conjugated cobalamin to deliver agents
04/03/2003CA2461666A1 Combination therapies for immune mediated diseases
04/03/2003CA2461603A1 Substituted amines for the treatment of neurological disorders
04/03/2003CA2461372A1 Dna sequences for human angiogenesis genes
04/03/2003CA2461363A1 Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
04/03/2003CA2461360A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors
04/03/2003CA2461144A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003CA2461142A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003CA2461136A1 A method of reducing the in vivo cholesterol ester transfer protein mediated transfer of cholesteryl esters between high density lipoproteins (hdl) and low density lipoproteins (ldl)
04/03/2003CA2461132A1 1, 8-naphthyridine derivatives as antidiabetics
04/03/2003CA2461095A1 Process for making substituted pyrazoles
04/03/2003CA2460953A1 Proteins associated with cell growth, differentiation, and death
04/03/2003CA2460787A1 Prevention and treatment of restenosis by local administration of drug
04/03/2003CA2460777A1 Thrombus/thrombogenesis inhibitors
04/03/2003CA2460344A1 Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
04/03/2003CA2459943A1 Androstanes as androgen receptor modulators
04/03/2003CA2458279A1 Modulation of vitamin storage
04/03/2003CA2456281A1 Pyrane derivatives as both ace- and nep- inhibitors
04/03/2003CA2455989A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003CA2455910A1 Ophthalmologic treatment methods using selective inos inhibitors
04/03/2003CA2453985A1 Receptors and membrane-associated proteins
04/03/2003CA2424770A1 Solid pharmaceutical preparation
04/02/2003WO2002028821A2 Propionic acid derivatives with ppar-alpha activating properties
04/02/2003EP1298206A1 Use of the Factor VII-activating protease for prevention and therapy of vaso-proliferative disorders
04/02/2003EP1298132A1 Hydropyridine derivative acid addition salts
04/02/2003EP1297851A1 Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
1 ... 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 ... 1595